07.12.2023
The prevalence of ophthalmic manifestations in COVID-19 ranges from 2 to 32%. The most common
06.12.2023
to be one of the most severe complications induced by a new coronavirus infection COVID-19. The mechanisms
06.12.2023
and 62 % in 2022 (the share decreased due to COVID-19). The share of DCS was 40 %, 32 % and 37.7 %; neoplasms
05.12.2023
The study examines the metaphors presented in demotivational posters during the COVID-19 pandemic
05.12.2023
of infectious diseases. The recent fight against the COVID-19 pandemic has proved the need to unite the efforts
04.12.2023
The COVID-19 crisis has disrupted traditional trade connections, significantly altering the global
04.12.2023
In this work, we set out to compare the immunogenicity of the Gam-COVID-Vac two-component vaccine
04.12.2023
morphological changes in the heart in patients who died from COVID-19.
Materials and methods. Autopsy material
02.12.2023
risk for severe clinical course of COVID-19. The high mortality rate due to COVID-19 and widespread
02.12.2023
had COVID-19. Endothelial dysfunction (ED) markers determination has been important in such patients
02.12.2023
Aim: to present a clinical case of post-COVID bronchiolitis in an adult.
Key points. A 54-year
02.12.2023
infection (COVID-19). The study aimed to compare sarilumab (SAR group) with tocilizumab (TOC group
01.12.2023
Objective: to evaluate the clinical status of patients with bronchial asthma in the post-Covid
01.12.2023
symptoms that appeared within 1–6 months after the infection (all patients had a history of COVID
30.11.2023
Numerous observations have proven the influence of COVID-19 on the formation of comorbid pathology
30.11.2023
Background. The professional training of students has dramatically changed over the COVID
30.11.2023
2016 to 2022.
The author evaluated the impact of COVID-19 pandemic on the pre-COVID incidence trends
29.11.2023
assessment tool and the Charlson Comorbidity Index in predicting mortality in cancer patients with COVID
29.11.2023
will allow for long-term protection against coronavirus disease 2019 (COVID-19).
Aim. To study the severity
29.11.2023
2019 (COVID-19) in a prospective registry.
Material and methods. Two-year outcomes (2,2±0,5) after
